> Our Impact > Scientific Retreat > Poster Abstracts

Poster Abstracts

Author	Abstract Title
Abel, Melissa	Association of PSA Doubling Time and PSMA PET Findings in Biochemically Recurrent Pca
Armstrong, Andrew	Therapy-induced stress signaling induces mitochondrially-mediated survival during AR blockade in PCa
Atmakuri, Aishwarya	Spatial Analysis of the TME reveals an immunosuppressive phenotype of tertiary lymphoid structures in localized high-risk and progressive PCa
Au, Cheuk Man (Cherie)	Dual AR/AR-V7 Molecular Glue Degrader Overcomes Therapeutic Resistance in Advanced PCa
Bakht, Martin	Spatial Mapping of Metabolic Escape: The AR–LAT1 Axis Defines an ¹⁸F-Fluciclovine–Avid State Across CRPC and NEPC
Barone, Francesca	Clinical and immunologic effects of aglatimagene besadenovec combined with RT in intermediate-risk localized PCa: integrated results from the PRTK03 and PRTK05 clinical trials
Berchuck, Jacob	Plasma Epigenomic Profiling Predicts Therapeutic Target Expression and Response to Cell-Surface-Targeted Therapy in Advanced PCa
Bernard-Tessier, Alice	Impact of DNA PK inhibition on 177-LuPSMA response in PSMA-low PCa models
Bhatia, Vipul	Nanobody-Based PSMA CAR T Cells Enable Safe Dual-Antigen Targeting of mCRPC
Boruah, Nabamita	Decoding PCa with BRCA germline mutation
Brault, Lise	Using EvoCaP Model To Reveal Therapy Driven Metastatic Dissemination in PCa
Burnham, Leanne	Diabetes and HER2 interact to modify PCa outcomes
Casanova-Salas, Irene	Integrated ctDNA and EV-RNA profiling reveals tumor evolution and phenotypic adaptation in metastatic PCa
Chakraborty, Goutam	Low-PSA Expressing High Risk PCa: Clinical Significance and Molecular Characterization
Chan, June	Effects of a Home-Based Walking Intervention on Serum Metabolomic Profiles in Men with PCa on Active Surveillance
Cheal, Sarah	Theranostic 89Zr/225Ac anti-CEACAM5 radioimmunotherapy for mCRPC
Chen, Feiyu	Divergent Roles of SPOP and CHD1 in ACSL4 Regulation Reveal Context-dependent Vulnerabilities for Targeting Ferroptosis
Chen, William	Spatial phenotypes in metastatic PCa associate with PSA response and early remodeling during [177Lu]Lu-PSMA-617 plus pembrolizumab
Chen, Xuanrong	MBD4 modulates prostate lineage and tumorigenesis by restricting FOXA1-driven enhancer reprogramming
Chesner, Lisa	ATM-deficient PCa cells exhibit therapeutic sensitivity to cell cycle checkpoint inhibition
Choi, Eunhee	HER2 IHC Discordance Across Serial PCa Biopsies
Chu, Carissa	A genome-scale CRISPR screen nominates LSD1 inhibition as a strategy to increase STEAP1 expression and enhance STEAP1-directed therapy in PCa
Connolly, Erin	Single-Cell Profiling Identifies a NAMPT-Centered Inflammatory Program Implicated in the Cardiovascular Toxicity of GnRH Agonist Therapy for PCa
Cooper, Paula	Links between the T cell receptor repertoire and patient outcomes in racially diverse men with PCa revealed by bulk and single cell analysis
Cooperberg, Matthew	A novel digital pathology artificial intelligence (DPAI) score improves prognostic estimation in patients with localized PCa
Daemen, Anneleen	Rinzimetostat, an allosteric EED inhibitor, promotes and maintains a luminal, AR-dependent phenotype with mechanistic confirmation in patients with mCRPC
De Sarkar, Navonil	FACT Inhibition with CBL0137 as a Novel Therapeutic Strategy for PSMAlow Aggressive-Variant PCa
Deng, Su	AI-Guided Functional Interrogation of Rare Mutations Reveals Hidden Drivers of Therapy Resistance in PCa
Diaz, Johnny	Human prostate chunkanoids give rise to AR+ cells to study cell-state dependent oncogenesis
Diehl, George	177Lu-PSMA-617 Targeted Radionuclide Therapy Increases the Efficacy of B7-H3 Targeted CAR-T Cell Therapy in PCa
Doultsinos, Dimitrios	Integration of stress response biology multi-omic datasets decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance
Fassl, Anne	Patient-Derived Ex Vivo PCa Models for the Development and Evaluation of Targeted Therapies
Fernandes, Rayzel	Investigating long non-coding RNAs as drivers of therapy resistance in PCa
Fletcher, Claire	Whole-Genome CRISPR Screening Identifies Clinically-Relevant and Differentially-Essential Genes in Enzalutamide-Resistant versus-Responsive PCa
Fu, Hangcheng	Prospective Chromatin Accessibility Signatures in MRI-Targeted Biopsy Lesions to Predict Active Surveillance Failure
Gaffney, Christopher	Spatial Immunophenotyping of Matched PCa Primary Tumors and Involved Lymph Nodes
Gauntner, Timothy	Androgen Deprivation Reprograms Human CD8+ T Cell Fate Through an AR–BHLHE40 Axis
Gicobi, Joanina	Metabolic synthetic lethality in SPOP-mutant PCa
Graham, Laura	Square Wave Testosterone Therapy in Metastatic PCa
Grunberg, Nil	Investigating the Potential of Repurposing GLP1R and GIPR Agonists for the Treatment of Obesity-Driven Aggressive PCa
Haas, Roni	Genetic determinants of cancer hallmark activities predict PCa risk and aggressiveness
Halabi, Susan	Genomic Predictors of Overall Survival and PSA Response in PARP Inhibitor-Treated mCRPC: A Meta-Analysis from the PRECISION Registry
Heath, Elisabeth	Trends in treatment patterns and outcomes among patients with metastatic androgen pathway modulation–resistant PCa (mAPMR) in real-world clinical practice: a PRECISION data platform analysis
Hodgson, Kirsty	Targeting Siglec-engaging immunosuppressive sialoglycans to suppress PCa bone metastasis
Hope, Thomas	Prospective, multicenter, first-in-human phase 1/2 study of 64Cu PSMA I&T investigating dosimetry, safety, and efficacy in men with biochemically recurrent metastatic PCa
Hsiung, Chris	Engineered CRISPR-Cas12a for combinatorial functional genomics in PCa
Hsu, Sarah	Decoding enhancer regulation in advanced PCa
Huang, Rong Rong	PSCA Complements PSMA Across Primary, Metastatic, and Post-Pluvicto PCa
Hurley, Paula	Cribriform morphology in intermediate grade PCa is defined by molecularly distinct subtypes
Jamieson, Christina	Targeting Colibactin, a genotoxic mutagen from E.coli, as a driver of genomic instability in PCa metastatic progression.
Jang, Albert	Plasma-derived extracellular vesicles and PSMA PET/CT imaging for predicting response to 177Lu-PSMA-617 in patients with metastatic PCa
Janopaul-Naylor, James	Beyond the Cores: MRI-Defined Extension and PSA Density Refine Risk in Gleason 7 PCa
Jia, Li	NDUFAF4-Driven Metabolic Vulnerabilities Guide Precision PARP Inhibition in PCa
Jimenez Vacas, Juan	Pharmacological activation of the GCN2-mediated integrated stress response enhances the efficacy of BH3 mimetics in castration-resistant PCa
Kensler, Kevin	GLP-1 receptor agonist and SGLT2 inhibitor use and weight change following ADT initiation among men with PCa
Kimmel, Blaise	Rational Protein Design and Modular Functionalization for Targeted Drug Delivery in Advanced PCa
Kotula, Leszek	Defining biology of ABI1-driven mechanism of treatment resistance to dual ADT/ARPI therapy
Kregel, Steven	A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes PCa proliferation
Ku, Anson	ELF3-associated club-like epithelial states are linked to immune infiltration in high-risk localized prostate cancer
Kumar, Rajendra	Autophagy as an adaptive survival pathway in androgen-mediated MYC suppression in PCa
Labanca, Estefania	Implications of ketone metabolism in progression to treatment refractory bone metastasis
Labbé, David	A large-scale patient-derived xenograft trial uncovers a CHK1 vulnerability in advanced PCa and a strategy to overcome resistance
Lallous, Nada	AR Condensates Promote Malignant Progression in Castration-Resistant PCa
Leiter, Amanda	Calibration of a Diabetes Microsimulation Model Improves Mortality Prediction in PCa Survivors
Li, Haolong	CRISPR Screening Identifies SLC7A5 as a Therapeutic Target to Enhance NK-Mediated Cytotoxicity in PCa
Liburd, Lincoln	Transcriptomics and Proteomics Analysis of Enzalutamide-Treated CRPC Cell Lines
Liu, Wenlong	Dual-Targeted CAR-γδ T Cells Overcome Antigen Heterogeneity in mCRPC
Loeb, Stacy	Usefulness of Podcasts to Provide Public Education on PCa Nutrition and Lifestyle
Lu, Guolan	Integrating Molecular Imaging with Spatial Omics to Track Drug Delivery through First-In-Human Trials
Luo, Jie	Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in PCa
Lyu, Aram	Identification of neutrophil-driven mechanisms underlying immunotherapy resistance in PCa bone metastasis
Maffei, Davide	The BeSpoke Decision Support decision aid for patients with newly diagnosed localised PCa – a single-blind randomised controlled trial
Mahajan, Kiran	Development and Characterization of a Novel Small Molecule KDM6A Inhibitor for Targeting Castration-Resistant Prostate Cancer
Mahajan, Nupam	Phase I, First-in-man Clinical Trial of `Dual’ AR antagonist/Immune modulator (R)-9b in CRPC patients (PHAROS)
Maher, Christopher	ERG mRNA Expression Predicts Benefit of Anti-androgen Therapy Added to Salvage Radiation in Recurrent PCa Patients: A Secondary Analysis of the NRG/RTOG 9601 Phase III Randomized Trial
Mannas, Miles	Prospective External Validation of Stimulated Raman Histology and Machine Learning for Rapid PCa Detection and Tumor-Enrichment from MRI-Targeted Biopsies
Morel, Katherine	Loss of tristetraprolin drives the progression to treatment resistant PCa by altering stress response pathways
Morton, Andrew	Development of a Domain-ALTeration Chimera (DALTAC) to Disrupt Polycomb Repressive Complex 2 in PCa
Murad, John	Combining Radiopharmaceutical Ligand Therapy with CAR T Cells to Overcome the Heterogeneous Immunosuppressive Prostate TME
Mustafi, Pallabi	Epigenetically Informed Therapeutic Strategies for DNA-Hypomethylated PCa
Nanda, Jagpreet Singh	Small Molecule Inhibitors of the Lineage Plasticity Driver ONECUT2
Nateghi, Ramin	Predicting PCa Luminal and Basal Subtypes from Routine Biopsy Images Using Artificial Intelligence
Nelson, Colleen	Translating MetAP2 inhibition in aggressive variant PCa: preclinical rationale for the EVADE-1 trial of SDX-7320 (evexomostat)
Nguyen, Charles	Treatment Sequencing Is Not Predictive of PARP Inhibitor Outcomes in Metastatic Castration-Resistant Prostate Cancer
Nouruzi, Shaghayegh	ASCL1-Driven Methionine Metabolism Is a Therapeutic Vulnerability in Neuroendocrine PCa
Pachynski, Russell	Phase 1 Trial of Personalized Neoantigen DNA Vaccines in Combination with Nivolumab, Ipilimumab, and PROSTVAC in Metastatic Androgen Pathway Modulator Sensitive PCa
Papachristodoulou, Alex	Establishment of pre-clinical models for the discovery of new mitochondrial biomarkers of high-risk PCa
Patel, Hiten	Image Based Phenotyping and an NLP system for PIRADS and Volume for Prostate MRI in VHA Radiology Reports
Patsch, Katherin	EMI-1725 Demonstrates Broad Antagonist Activity Against Drug-Resistant AR Mutations and Tumor Growth Suppression in Preclinical Models of mCRPC
Patton, Robert	Uncertainty-aware functional profiling of metastatic PCa from cell-free DNA
Poluben, Larysa	NFIB licenses androgen receptor cistrome reprogramming during the transition from normal prostate epithelium to PCa
Rajwa, Pawel	Real-World Evaluation of Adverse Events Associated with Systemic Therapies for Metastatic PCa
Rodrigues, Silvia	Breaking the fat chain: FASN inhibition and exogenous PUFAs as a double hit against PCa progression.
Rojo Domingo, Mariluz	Detection and localization of unfavorable-histology PCa using MRI and whole-mount histopathology
Romero, Rodrigo	Deconstructing Lineage Plasticity: Mapping Determinants of the Neuroendocrine Transition
Roy, Soumyajit	Multimodal Risk Stratification in PCa Using Digital Pathology Artificial Intelligence and Genomic Classification
Sabater, Agustina	Targeting FGFR disrupts the reciprocal interplay between PCa and bone
Sachdeva, Ashwin	CT-derived body composition as a prognostic and predictive biomarker in high-risk/metastatic hormone-sensitive PCa: exploratory analysis of the STAMPEDE trials
Salari, Keyan	The Utility of Enhanced Screening for People with Inherited Risk of Developing Aggressive PCa in the PATROL Study
Saliji, Mark	A Tumour-Nerve-Adipose Metabolic Dependency Axis involving N-Acetyl Aspartate (NAA) and Glutamate Carboxy Peptidases (PSMA)
Sanin, David	Type I Interferon priming in macrophages is associated with poor outcomes in patients with advanced PCa
Scheinberg, Tahlia	Pharmacodynamic effects of ribociclib in non-metastatic PCa: the LEEP randomised trial
Schmidt, Daniel	PKM2 Activation Sensitizes Radioresistant Tumors to Therapy by Disrupting Serine Synthesis Under Reductive Stress
Schweizer, Michael	Efficacy and Safety of Mevrometostat (<) in Combination with Enzalutamide (E) in Patients (Pts) with Metastatic Castration-Resistant PCa (mCRPC): Data from a Phase 1 Study
Scurll, Joshua	Pathologic responses and their molecular correlates in the phase-II Genomic Umbrella Neoadjuvant Study (GUNS) of genomic-biomarker-directed triplet therapies in high-risk localized PCa
Semenova, Galina	Overcoming Apoptosis Resistance in Advanced PCa with ADC Combinations and Dual- Payload ADCs
Sena, Laura	A study of 7 days of water-only fasting or ketone supplementation in patients with PCa
Sharifi, Marina	Integrated high purity CTC RNA-Seq and ctDNA sequencing to define the intersection of high-risk genomic alterations and transcriptional phenotypes in metastatic PCa via liquid biopsy
Shibata, Maho	HER2 Expression is Associated with Altered Membrane Morphology in PCa
Shobaki, Nour	TRI-CAR: Aim, Arm, and Armor-CAR-T Against PCa
Shore, Neal	Real-world treatment patterns and outcomes in patients with metastatic androgen pathway modulation–resistant PCa (mAPMR) who have previously received (ARPI), taxane, and 177Lu-PSMA-617 therapy: a PRECISION data platform analysis
Shotts, Kristin	Beyond PSA Depth: Longitudinal PSA Kinetics Reveals Treatment Modality-Specific Prognostic Windows in Metastatic PCa
Shrestha, Raunak	Spatial Mapping of Accessible Chromatin Landscapes in PCa
Sim, Woogwang	Resistance to CD47-directed Macrophage Immunotherapy Identifies TREM2 as a Rationale for Dual Macrophage Checkpoint Blockade in Lethal PCa
Sowalsky, Adam	Organ-specific fitness shapes lineage plasticity in metastatic PCa
Su, Allen	Elevated RAD21 levels promote immune evasion in PCa
Sutera, Philip	Opening the Black Box: Biologic Pathways Underlying a Clinically Validated Multimodal Digital Pathology AI Biomarker in Metastatic PCa
Taylor, Amy	Investigating Relationships amongst Intrinsic and Acquired Genomic Alterations on Overall Survival in Metastatic PCa
Tendler, Salomon	DLL3-Directed ²²⁵Ac Radioimmunotherapy Produces Durable Tumor Responses in a NEPC Model
Tolmeijer, Sofie	Circulating tumor DNA assessments for response to 177Lu-PSMA-617 with ipilimumab and nivolumab in metastatic PCa: results from the randomized phase II EVOLUTION trial (ANZUP 2001)
Tsao, Phoebe	Impact of androgen receptor pathway inhibitors on mental health in Veterans with metastatic androgen pathway modulation-naive PCa
Vasilis, Stavrinides	Radiological and histological evolution of prostate cancer during active surveillance
Venkadakrishnan, Varadha Balaji	L-Myc is a lineage-specific driver of neuroendocrine transformation in PCa
Wala, Jeremiah	Whole-slide CyCIF and archive-scale H&E digitization characterize immune-organized primary PCa
Washington III, Samuel	Patient reported health-related social needs and care disruptions in the outpatient cancer clinic
Wu, Jennifer	Novel antibody targeting soluble and tumor-bound NKG2D ligand MIC reshapes tumor immune ecosystem and is ready for clinical evaluation in mCRPC under an approved IND
Xu, George	Cribriform Status at Follow-up Biopsy Is Critical for Predicting Active Surveillance Failure in the Magnetic Resonance Imaging Era
Xu, Jianfeng	GenProb-PCSM: Germline Risk Stratification for Lethal PCa Across Ancestry Groups
Yang, David	Immune spatial organization predicts metastasis risk in aggressive localized PCa
Younger, Noah	Characterizing PRC1 as a Mediator of Enzalutamide Resistance in Advanced PCa
Zhang, Zeda	Targeting a stress-adaptive, stem-like tumor state in metastatic castration resistant PCa with uPAR-directed therapy
Zhu, Xiaolin	Targeting SSTR1 to overcome resistance to ARSI in PCa

ABSTRACT GUIDELINES:

Abstracts must be submitted on the PCF Retreat registration website.
The font must be in Tahoma, 10pt. Please make sure all formatting and special characters are displayed properly before submission. Failure to follow formatting guidelines may result in incorrect display of your abstract.
Abstracts must include: Title, Authors, Affiliations, Background, Methods, Results, Conclusions, Funding Acknowledgements, and a Conflicts of Interest Disclosure Statement. *Failure to include any of these fields may result in a delay of review and/or acceptance of your abstract.
Word limit is 450 words. The word limit applies only to the abstract body (Background, Methods, Results, Conclusions).
Figures and tables may be included in the abstract, and do not count towards the word limit.
Authors may submit more than one abstract for consideration on separate projects.
Trials in progress (TIPs) and encore abstracts are allowed, however the inclusion of previously unpublished and unpresented data is preferred.
The poster may be presented by any author on the study or their representative, with permission from the primary author(s).

Poster Presentation Guidelines
Each poster must be a minimum of 36′′ x 48′′ and cannot exceed 48′′ vertically x 84′′ horizontally. We will not be able to accommodate posters greater than 48′′ vertically.

Any questions about abstracts or posters should be directed to [email protected]. The deadline to submit abstracts is September 2, 2026.